- Home
- MLKN vs CGEM Comparison
MLKN vs CGEM Comparison
Compare MLKN & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLKN | CGEM |
|---|---|---|
| Founded | 1905 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 904.7M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MLKN | CGEM |
|---|---|---|
| Price | $16.23 | $13.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $30.13 |
| AVG Volume (30 Days) | 653.3K | ★ 1.1M |
| Earning Date | 03-25-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $3,669,900,000.00 | N/A |
| Revenue This Year | $5.94 | N/A |
| Revenue Next Year | $3.78 | $5.20 |
| P/E Ratio | $15.91 | ★ N/A |
| Revenue Growth | ★ 1.14 | N/A |
| 52 Week Low | $13.77 | $5.68 |
| 52 Week High | $23.18 | $16.74 |
Technical Indicators
Market Signals| Indicator | MLKN | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 57.59 | 44.43 |
| Support Level | $13.87 | $11.92 |
| Resistance Level | $16.41 | $16.31 |
| Average True Range (ATR) | 0.58 | 1.25 |
| MACD | 0.11 | -0.27 |
| Stochastic Oscillator | 85.41 | 35.58 |
Price Performance
Historical ComparisonAbout MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.